Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$100.83 -3.9%	$106.48	$72.21 ▼ $139.13	$5.17B	0.46	606,771 shs	854,936 shs
EVTCY Evotec	$4.05 +6.0%	$4.11	$14.22 ▼ $26.57	$1.34B	0.98	2,407 shs	96,826 shs
LNTH Lantheus	$72.93 +2.8%	$78.22	$69.12 ▼ $118.21	$4.91B	0.12	1.08 million shs	615,452 shs
TLX Telix Pharmaceuticals	$14.20 +2.2%	$16.40	$13.61 ▼ $30.36	$4.70B	N/A	49,572 shs	76,204 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-1.31%	-6.48%	+0.68%	-1.22%	+23.16%
EVTCY Evotec	+2.69%	-9.48%	+0.26%	-9.26%	-20.08%
LNTH Lantheus	-3.25%	-3.63%	-12.38%	-30.30%	-37.59%
TLX Telix Pharmaceuticals	-4.73%	-13.94%	-15.36%	-26.12%	+1,388,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.7417 of 5 stars	4.5	1.0	0.0	4.5	2.7	4.2	0.6
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	4.7027 of 5 stars	3.4	2.0	0.0	4.2	4.0	2.5	1.9
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	70.91% Upside
EVTCY Evotec	0.00	N/A	N/A	N/A
LNTH Lantheus	2.83	Moderate Buy	$131.20	79.90% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.33	57.28% Upside

Current Analyst Ratings Breakdown

Latest EVTCY, AXSM, TLX, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/9/2025	TLX Telix Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
7/3/2025	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/12/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/5/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00

(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	12.87	N/A	N/A	$1.18 per share	85.45
EVTCY Evotec	$572.16M	2.34	$0.04 per share	105.53	$2.52 per share	1.61
LNTH Lantheus	$1.53B	3.29	$7.29 per share	10.00	$15.65 per share	4.66
TLX Telix Pharmaceuticals	$516.72M	9.30	$0.12 per share	121.64	$1.12 per share	12.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	35.76	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
EVTCY Evotec	$7.14M	$0.41	9.88	∞	N/A	20.85%	16.02%	7.81%	N/A
LNTH Lantheus	$312.44M	$3.52	20.72	11.56	N/A	16.55%	36.99%	20.55%	8/6/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	29.58	N/A	N/A	N/A	N/A	8/20/2025 (Estimated)

Latest EVTCY, AXSM, TLX, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	H1 2025	TLX Telix Pharmaceuticals	$0.2160	N/A	N/A	N/A	$316.69 million	N/A
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
EVTCY Evotec	0.53	2.57	2.50
LNTH Lantheus	0.49	5.74	5.46
TLX Telix Pharmaceuticals	0.99	2.78	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
EVTCY Evotec	N/A
LNTH Lantheus	99.06%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
EVTCY Evotec	N/A
LNTH Lantheus	1.50%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
EVTCY Evotec	4,200	330.22 million	N/A	Not Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.40 million	N/A	N/A

EVTCY, AXSM, TLX, and LNTH Headlines

Recent News About These Companies

Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - What's Next?

July 25 at 4:34 PM | marketbeat.com

Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 24 at 3:19 PM | tmcnet.com

Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

July 24 at 3:00 PM | businesswire.com

Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 24 at 2:13 PM | businesswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's Why

July 24 at 1:41 PM | marketbeat.com

Equities Analysts Offer Predictions for TLX FY2025 Earnings

July 24 at 8:41 AM | marketbeat.com

INVESTOR ALERT: Investigation of Telix Pharmaceuticals Limited (TLX) Announced by Holzer & Holzer, LLC

July 23 at 5:02 PM | globenewswire.com

Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced â€“ Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

July 23 at 2:40 PM | businesswire.com

Telix Pharmaceuticals stock drops as SEC probes disclosures tied to cancer treatment

July 23 at 8:02 AM | msn.com

Telix sinks as US regulator SEC issues subpoena over claims

July 23 at 3:01 AM | msn.com

Why did the Telix share price just crash 16%?

July 23 at 3:01 AM | msn.com

Telix Pharmaceuticals (ASX:TLX) Confirms 2025 Revenue Forecast Between A$770 Million To A$800 Million

July 22 at 4:56 PM | finance.yahoo.com

Telix Reports $204M Revenue, Up 63% YOY

July 22 at 4:06 AM | globenewswire.com

William Blair Brokers Decrease Earnings Estimates for TLX

July 17, 2025 | americanbankingnews.com

William Blair Has Negative Outlook of TLX FY2025 Earnings

July 16, 2025 | marketbeat.com

Missing the first double on this biotech star

July 15, 2025 | msn.com

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

July 15, 2025 | msn.com

Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially ...

July 11, 2025 | insidermonkey.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Should You Sell?

July 10, 2025 | marketbeat.com

Gozellix Receives Permanent HCPCS Code

July 9, 2025 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - What's Next?

July 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVTCY, AXSM, TLX, and LNTH Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$100.83 -4.14 (-3.94%)

Closing price 04:00 PM Eastern

Extended Trading

$102.78 +1.95 (+1.93%)

As of 07:36 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Evotec OTCMKTS:EVTCY

$4.05 +0.23 (+6.02%)

As of 07/24/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Lantheus NASDAQ:LNTH

$72.93 +2.00 (+2.82%)

Closing price 04:00 PM Eastern

Extended Trading

$73.20 +0.27 (+0.37%)

As of 07:55 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$14.20 +0.31 (+2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$14.10 -0.10 (-0.70%)

As of 07:25 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time